Navigation Links
Gerresheimer Reports Strong Revenues and Earnings Growth in the Second Quarter
Date:7/13/2011

DUESSELDORF, Germany, July 13, 2011 /PRNewswire/ --


 

  • Group revenues grow by 7.6 percent at constant exchange rates in the second quarter of 2011
  • Adjusted EBITDA margin is 19.8 percent
  • Net income increases to EUR 13.3m
  • Successful conclusion of refinancing

Gerresheimer AG, one of the leading global suppliers to the pharma and healthcare industry, has closed successfully the second quarter of the 2011 financial year. "We have achieved strong growth in revenues and net income. Our Moulded Glass and Plastic Systems Divisions have performed particularly well. We have also strengthened our operations in South America, a strategically important market for us, through our acquisition of Vedat," said Uwe Röhrhoff, CEO of Gerresheimer AG.

Gerresheimer was able to achieve marked growth in revenues in the second quarter of the 2011 financial year (March 1, 2011 to May 31, 2011) of 5.9 percent to EUR 284.5m. At constant exchange rates, revenue growth was 7.6 percent. The Moulded Glass and Plastics Systems Divisions played an important role in generating this strong growth. Growth drivers of the Plastic Systems division included inhalers, insulin pens, diagnostic systems and plastic packaging products. Vedat, the company that Gerresheimer acquired in March, has an excellent position in the South American primary pharmaceutical plastic packaging market and has contributed to the positive development. Gerresheimer recently announced plans to extend its Czech Republic plant, being part of the fast-growing Plastic Systems division.

Gerresheimer reports adjusted EBITDA of EUR 56.3m (prior year: EUR 56.3m) for the second quarter of 2011. The adjusted EBITDA margin was 19.8 percent (Q2 2010: 20.9 percent). Scheduled overhauls of furnaces and capacity restrictions on prefillable syringe system production were due in the second quarter. Net income increased year on year, despite one-off expenses in connection with refinancing, by EUR 2.1m to EUR 13.3m. Adjusted earnings per share increased over the previous year's quarter from EUR 0.59 to EUR 0.69.

Net financial debt has declined by EUR 4.1m to EUR 404.6m since the prior year, despite the costs incurred in connection with the Vedat acquisition, dividend payment and refinancing. In May, Gerresheimer concluded the refinancing process, which it had started ahead of schedule, with five and seven-year maturities.

"As a full-service partner for glass and plastics products and systems for the global pharma and healthcare industry we have a unique positioning. There is worldwide growth in demand for intelligent drug delivery and primary packaging solutions. Our competence enables us to make a decisive contribution to health and well-being," said Röhrhoff.

Outlook

Gerresheimer is expecting growth in revenues at constant exchange rates of six to seven percent, including the Vedat business, and an adjusted EBITDA margin of approximately 20 percent in the current 2011 financial year. The investment volume is expected to be around EUR 80m.

Cross-reference: Press release including Group Key Figures is available at http://www.presseportal.de/pm/9072/gerresheimer_ag

Gerresheimer AG
Jens Kürten
Director Corporate Communication & Marketing
Telephone +49-211-6181-250
Fax +49-211-6181-241
E-Mail j.kuerten@gerresheimer.com

Internet http://www.gerresheimer.com



'/>"/>
SOURCE Gerresheimer AG
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Gerresheimer Reports Strong Earnings and Sales Growth
2. Substantial Revenues and Earnings Plus for Gerresheimer
3. Moodys Raised Outlook for Gerresheimer
4. Gerresheimer Achieves Sales Target for 2009
5. Gerresheimer has Passed the Turning Point
6. LCA-Vision Reports 2011 Second Quarter Procedure Volume
7. ChemoCentryx Reports Novel CCR2 Antagonist Significantly Improves Kidney Function and Hyperglycemia in Models of Type 2 Diabetes
8. ReportsnReports - Multitargeted Therapies: Promiscuous Drugs and Combination Therapies
9. BioDrain Medical, Inc. Reports Results of Annual Meeting
10. Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders
11. Enzymatics Reports Latest Growth Figures; Confirms Massachusetts Emerging Role as Leading Bio-manufacturing Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... PUNE, India , January 16, 2017 ... titled, "Vital Signs Monitoring Devices Market by Type and End ... the global vital signs monitoring devices market size was worth ... million by 2022, growing at a CAGR of 5.8% from ... the leading regional market in global vital signs monitoring devices ...
(Date:1/16/2017)... and PUNE, India , January ... new report published by Allied Market Research, titled, "Sterilization ... Analysis and Industry Forecast, 2014-2022," the global sterilization technologies ... from $5,768 million in 2015, growing at a CAGR ... gas sterilization segment dominated the market in 2015, with ...
(Date:1/16/2017)... PORTLAND, Oregon and PUNE, India , January 16, ... Market Research, titled, "Antioxidants Market by Type - Global Opportunity Analysis and Industry ... and is expected to reach $4,531 million by 2022, registering a CAGR of ... accounted for more than one-third share of the global volume in 2015. ... ...
Breaking Medicine Technology:
(Date:1/16/2017)... Maryland (PRWEB) , ... January 16, 2017 , ... ... Thibodeau has been appointed Chief Executive Officer of the medical device company, effective ... Vixiar Chairman Robert Storey. “Kevin has a strong track record in medical ...
(Date:1/15/2017)... ... January 15, 2017 , ... Whole Health Supply, LLC is announcing the release of an ... new avenues for purchase. , The 2017 edition has wide jaws that will accommodate ... older boomers as well as diabetics. This handle is reinforced for extra strength when pressing ...
(Date:1/15/2017)... ... January 14, 2017 , ... Wondering where to go ... delivered straight to your door for a romantic, lobster feast in the comfort of ... for Valentine's Day. The dinners will be featured until February 15th, 2017. , ...
(Date:1/14/2017)... , ... January 13, 2017 , ... ... and Soul, incorporating a magnesium-rich Mediterranean diet may lower the risk of type ... Lounge notes that the many health and wellness benefits linked to a Mediterranean ...
(Date:1/13/2017)... ... ... The 18th European Congress: Perspectives in Lung Cancer will be held in ... is expertly designed to meet the educational needs of European oncology clinicians and researchers ... Dr. Giorgio V. Scagliotti, Professor of Oncology at the University of Torino, and organized ...
Breaking Medicine News(10 mins):